智通财经APP获悉，Organovo Holdings今日宣布，礼来(LLY.US)（Eli Lilly and Company）将收购该公司旗下的FXR项目及主打疗法FXR314。FXR314是一款潜在“best-in-class”的口服FXR小分子激动剂。目前，Organovo已获得美国FDA的临床试验许可，正在进行其主打疗法FXR314用于治疗溃疡性结肠炎（UC）的2期试验。
公司通过其专有的3D人体组织模型，制定了针对FXR314的高效临床开发策略，该策略不仅适用于溃疡性结肠炎，也可用于治疗包括克罗恩病在内的其他炎症性肠病。Organovo同时推动FXR314在治疗肝脏疾病方面的应用，包括代谢相关性脂肪性肝炎（MASH）和原发性胆汁性胆管炎。初步临床试验结果表明，FXR314具备高效力、安全性和良好耐受性，并有望规避其他FXR靶向药物常见的剂量限制性毒性问题。
根据协议，Organovo将获得一笔预付款，并在FXR314达成关键监管和商业里程碑时获得相应款项。礼来则将获得Organovo的FXR项目在全球范围内的全部商业开发权利。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.